Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 8/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | KDM5A | P29375 | 1/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2954443 | 0.87 | MAPT (0.60) | MRGPRX4PTGER1F2ELANE | |
| SCHEMBL11846878 | 0.85 | PTGER1 (0.53) | MRGPRX4SLC6A4PTGER1 | |
| SCHEMBL9076683 | 0.84 | HTR2C (0.53) | SLC6A4 | |
| SCHEMBL15778925 | 0.84 | SLC6A4 (0.53) | MRGPRX4SLC6A4PTGER1ALDH1A1SMN1; SMN2 | |
| SCHEMBL561548 | 0.84 | SLC6A4 (0.51) | MRGPRX4SLC6A4PTGER1PLAUKDM5A | |
| SCHEMBL18906416 | 0.83 | ELANE (0.49) | MRGPRX4NPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL7907404 | 0.82 | ALOX5 (0.54) | F2ELANE | |
| SCHEMBL2853160 | 0.81 | APP (0.49) | F2ELANE | |
| SCHEMBL16064489 | 0.81 | USP28 (0.57) | SLC6A4PTGER1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL4698492 | 0.81 | TSHR (0.48) | NPC1ALDH1A1TP53RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3763367-A1 | PYRIDINE-PYRAZOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3763367-A1 | PYRIDINE-PYRAZOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-2928471-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-2928471-B1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2020-10-14 | — | — | EP | disclosed |
| US-10173996-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10173996-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-9908865-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908865-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908865-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170275266-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20120035237-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS | COE DIANE MARY (GB) | 2012-02-09 | — | — | US | disclosed |
| US-20120035237-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS | COE DIANE MARY (GB) | 2012-02-09 | — | — | US | disclosed |
| US-20120035237-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS | COE DIANE MARY (GB) | 2012-02-09 | — | — | US | disclosed |
| WO-2010122089-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010122089-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010122088-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010122088-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10173996-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | MRGPRX4 3645/4885SLC6A4 4450/4885PTGER1 2733/4885 |
| US-20170275266-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | MRGPRX4 3645/4885SLC6A4 4450/4885PTGER1 2733/4885 |
| US-20120035237-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS | RYR2, PAICS, CTRC | MRGPRX4 1178/4885SLC6A4 4252/4885PTGER1 1951/4885 |
| US-20100273744-A1 | COMPOUNDS | LTC4S, HRH4, HRH2 | MRGPRX4 71/4885SLC6A4 4312/4885PTGER1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.